ArriVent Says Cancer Drug Candidate Firmonertinib Misses Primary Endpoint in Phase 3 Trial; Shares Fall Pre-Bell
MT newswire2026/10/06 12:5008:50 AM EDT, 10/06/2026 (MT Newswires) -- ArriVent BioPharma's (AVBP) phase 3 Furvent trial of firmonertinib did not achieve its primary progression-free survival goal in previously untreated patients with EGFR exon 20 insertion-mutated non-small cell lung cancer, the company said Tuesday. According to the study, media progression-free survival was 11 months for the 240mg firmonertinib dose; 8.4 months for 160mg, and 9.5 months for the control arm, while confirmed response rates were 60%, 35% and 33%, respectively. The safety profile was consistent with prior studies, with no new safety signals. Grade 3 or higher adverse events occurred in 52% of patients on the 240mg dose, 53% on the 160mg dose, and 55% in the control arm, the company said. Shares of ArriVent fell more than 56% in recent premarket activity Tuesday. Price: 12.50, Change: -15.96, Percent Change: -56.08
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jensen Huang's influence surpasses that of Nvidia— and that's exactly the problem
Jensen Huang has been the key driving force behind the massive expansion of AI infrastructure, with his personal credibility and authoritative decision-making deeply embedded in the narrative of the global tech market’s rise over the past three years. Now, as scandals emerge, Nvidia’s trading team is expected to become more conservative and slow down external financing commitments, which undoubtedly worsens the situation for neoclouds already facing tight funding.
Crypto prices
More
